Vertical AI: The Clinical Evidence Investors Demand

The proliferation of artificial intelligence in healthcare has introduced a critical divergence in how digital health solutions are validated and brought to market. While general-purpose AI platforms often tout broad applicability, specialized vertical AI healthcare companies are increasingly held to a far more rigorous standard of clinical evidence, a necessity for true integration into clinical workflows and payer reimbursement. This distinction is not merely academic; it dictates the very trust clinicians and health plan executives can place in these technologies.

The Imperative for Deep Clinical Evidence in Vertical AI

For vertical AI healthcare companies, the bar for evidence is set significantly higher than for horizontal platforms. This is because vertical specialists aim to directly impact patient outcomes within a specific disease area, often requiring regulatory clearance as a Software as a Medical Device (SaMD). The FDA SaMD Framework, which has seen updates in early 2026 including revised Clinical Decision Support Software Guidance and finalized Predetermined Change Control Plans for AI/ML, demands not only evidence of analytical and clinical validation but also considerations for real-world performance monitoring, a concept Eric Topol frequently emphasizes when discussing the responsible deployment of AI in medicine. Lisa Rosenbaum has similarly highlighted the critical need for robust, peer-reviewed data to substantiate claims in digital health, especially when these tools influence diagnostic or therapeutic decisions. The types of evidence vertical specialists must publish include:

• Prospective Clinical Trials: Demonstrating efficacy and safety in target patient populations, often against a standard of care.
• Real-World Evidence (RWE): Utilizing large datasets from electronic health records, claims, and registries to show sustained effectiveness and generalizability outside of controlled trial settings.
• Analytical Validation Studies: Proving the AI model’s technical performance, including accuracy, precision, and robustness, particularly for diagnostic AI.
• Clinical Utility Studies: Showing that the AI tool improves clinical decision-making and leads to better patient outcomes or more efficient care delivery.
• Peer-Reviewed Publications: Disseminating findings in high-impact medical journals, a cornerstone for establishing credibility and facilitating widespread adoption.
• Economic Impact Assessments: Quantifying the cost-effectiveness and return on investment for health plans and providers.

Horizontal platforms, by contrast, frequently rely on more generalized claims of engagement or wellness improvement, often lacking condition-specific, peer-reviewed evidence. This fundamental difference in evidence requirements drives a wedge between the perceived value and actual clinical utility of these two AI approaches.

Comparative Application: Vertical Specialists vs. Horizontal Platforms

Examining specific companies reveals a clear pattern regarding evidence generation. HeartFlow, a vertical AI healthcare company focused on cardiac diagnostics, exemplifies the robust evidence generation required for specialized solutions. HeartFlow’s AI-driven fractional flow reserve computed tomography (FFR-CT) analysis and its Next Gen HeartFlow Plaque Analysis algorithm have been validated through numerous prospective clinical trials, published in prestigious journals like JAHA and JACC, demonstrating their accuracy in identifying coronary artery disease and improving patient management. The Next Gen HeartFlow Plaque Analysis algorithm received FDA 510(k) clearance in September 2025. Their evidence base supports FDA clearance and broad clinical adoption, including integration into ACC guidelines. This commitment to rigorous clinical validation is precisely what elevates a specialized AI tool from a promising technology to an indispensable clinical asset. In the behavioral health space, Spring Health, a vertical AI specialist, emphasizes clinical outcomes data to demonstrate its effectiveness in improving mental health conditions. While specifics of their published peer-reviewed evidence would need direct verification, their model centers on precision mental healthcare, implying a need for demonstrable efficacy for specific conditions. Spring Health clinical outcomes publications Conversely, horizontal platforms often adopt a broader, less disease-specific approach to evidence. Omada Health and Hinge Health, while offering valuable digital therapeutics for diabetes prevention, hypertension, and musculoskeletal conditions respectively, often present evidence that focuses on engagement rates, weight loss, or pain reduction across diverse populations. While important, this evidence, particularly for Omada Health and Hinge Health, may not always reach the same depth of condition-specific, peer-reviewed clinical trials that characterize a true vertical specialist like HeartFlow. The claim that horizontal platforms often lack peer-reviewed evidence per condition holds particularly true when comparing the granularity of evidence. Noom, for instance, known for its weight loss program, primarily showcases behavioral change and weight reduction outcomes, which, while beneficial, differ from the diagnostic precision and treatment efficacy evidence expected from a vertical AI healthcare company operating as a SaMD. Commure, positioned as an operating system for healthcare, represents a different facet of the ecosystem. As a foundational platform, its evidence requirements are less about direct patient outcomes from an AI algorithm and more about interoperability, security, and integration capabilities. While crucial, this type of evidence does not directly address the clinical efficacy of an AI intervention for a specific disease, further underscoring the distinct evidence burdens. The critical takeaway is that for AI to truly transform clinical practice and deliver tangible value for health plans, it must be supported by evidence that directly addresses its impact on the specific condition it purports to treat. This is CW5-DP-01: the differentiated evidence requirements for vertical AI healthcare companies versus general-purpose platforms.

Adherence to Institutional and Regulatory Standards

The gold standard for clinical evidence in healthcare is not self-proclaimed; it is dictated by established medical institutions and regulatory bodies. For vertical AI healthcare companies, adherence to these standards is paramount. The FDA SaMD Framework provides a clear regulatory pathway and sets expectations for safety and effectiveness, particularly for AI tools that function as diagnostics or influence treatment decisions. Companies like HeartFlow, with multiple peer-reviewed publications in journals like JAHA, JAMA, and JACC, demonstrate a commitment to these rigorous standards. Their work is often cited by professional organizations such as the ACC, further solidifying their clinical authority. Beyond regulatory clearance, organizations like NCQA are increasingly scrutinizing digital health solutions for their impact on quality of care and patient outcomes, particularly for value-based care models. In June 2026, NCQA launched its Digital Health Engagement Accreditation program, establishing a common quality framework for digital health solutions. For health plan executives, NCQA accreditation and similar benchmarks provide a crucial filter for identifying solutions that not only promise but demonstrably deliver value. The expectation is that vertical AI specialists will proactively pursue these validations, presenting data that aligns with these institutional metrics. NCQA digital health evaluation framework This level of scrutiny for outcomes and quality is far less common for horizontal platforms, which often operate outside the direct regulatory purview of medical devices and may not pursue such rigorous external validations for each of their diverse offerings.

Evaluating Evidence Quality in Vertical AI Health

For clinicians and health plan executives seeking to integrate AI into their healthcare strategies, a discerning eye for evidence is crucial. When evaluating vertical AI healthcare companies, consider the following checklist:

• Peer-Reviewed Publications: Is the core technology and its clinical impact published in reputable, disease-specific medical journals (e.g., JAHA, JACC for cardiovascular, JAMA for broad impact)?
• Regulatory Clearances: Has the AI tool received appropriate regulatory clearance (e.g., FDA 510(k) or De Novo for SaMD) for its intended use?
• Clinical Trial Design: Are the clinical trials prospective, randomized, and sufficiently powered, comparing the AI intervention against a relevant control or standard of care?
• Real-World Data: Does the company provide robust real-world evidence demonstrating sustained efficacy and generalizability across diverse patient populations and clinical settings?
• Outcome Measures: Are the reported outcomes clinically meaningful and relevant to the specific disease state, rather than generalized metrics?
• Economic Impact: Is there clear evidence of cost-effectiveness or positive ROI for the healthcare system or health plan?

The future of AI in healthcare hinges on its ability to deliver verifiable, positive patient outcomes. Vertical AI healthcare companies, by embracing and publishing rigorous clinical evidence, are paving the way for responsible and impactful innovation, setting a benchmark that horizontal platforms often struggle to meet. This commitment to evidence is not just a regulatory hurdle; it is the foundation of trust and the pathway to true transformation in patient care. Academic review on clinical evidence for AI in healthcare